Roivant Sciences Ltd [ROIV] Revenue clocked in at $103.15 million, down -6.95% YTD: What’s Next?

Roivant Sciences Ltd [NASDAQ: ROIV] price surged by 0.97 percent to reach at $0.1. The company report on December 20, 2023 at 4:30 PM that Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease.

This Phase 2 proof-of-concept trial is an open-label study to assess the safety and efficacy of batoclimab in Graves’ disease. Patients who are hyperthyroid despite treatment with an anti-thyroid medication (ATD) for more than 12 weeks are being enrolled to receive once-weekly subcutaneous (SC) injections of 680 mg batoclimab for 12 weeks followed by once-weekly SC injections of 340 mg batoclimab for 12 weeks. Treatment response is defined as normalization of T3 and T4 hormone levels without increasing ATD dose. The primary and secondary outcome measurements of the trial are being measured at weeks 12 and 24. This design allowed for efficacy assessments between two distinct ranges of IgG reductions.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


The one-year ROIV stock forecast points to a potential upside of 35.49. The average equity rating for ROIV stock is currently 1.17, trading closer to a bullish pattern in the stock market.

Guru’s Opinion on Roivant Sciences Ltd [ROIV]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ROIV shares is $16.20 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ROIV stock is a recommendation set at 1.17. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

Piper Sandler have made an estimate for Roivant Sciences Ltd shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on January 05, 2024.

The Average True Range (ATR) for Roivant Sciences Ltd is set at 0.43, with the Price to Sales ratio for ROIV stock in the period of the last 12 months amounting to 81.44. The Price to Book ratio for the last quarter was 8.82, with the Price to Cash per share for the same quarter was set at 1.76.

ROIV Stock Performance Analysis:

Roivant Sciences Ltd [ROIV] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.78. With this latest performance, ROIV shares gained by 4.92% in over the last four-week period, additionally sinking by -2.61% over the last 6 months – not to mention a rise of 19.02% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ROIV stock in for the last two-week period is set at 45.33, with the RSI for the last a single of trading hit 38.96, and the three-weeks RSI is set at 48.56 for Roivant Sciences Ltd [ROIV]. The present Moving Average for the last 50 days of trading for this stock 10.20, while it was recorded at 10.48 for the last single week of trading, and 10.11 for the last 200 days.

Insight into Roivant Sciences Ltd Fundamentals:

Roivant Sciences Ltd’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.82 and a Current Ratio set at 5.84.


With the latest financial reports released by the company, Roivant Sciences Ltd posted -0.49/share EPS, while the average EPS was predicted by analysts to be reported at -0.39/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -25.60%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ROIV.

Roivant Sciences Ltd [ROIV] Institutonal Ownership Details

The top three institutional holders of ROIV stocks are: VANGUARD GROUP INC with ownership of 1.3 billion shares, which is approximately 8.2815%. BLACKROCK INC., holding 1.03 billion shares of the stock with an approximate value of $176.59 billion in ROIV stocks shares; and BERKSHIRE HATHAWAY INC, currently with $156.75 billion in ROIV stock with ownership which is approximately 5.8325%.